MAFLD-related hepatocellular carcinoma: Exploring the potent combination of immunotherapy and molecular targeted therapy

被引：2

作者：

Guo, Ziwei ^{[1
]}

Yao, Ziang ^{[2
]}

Huang, Bohao ^{[3
]}

Wu, Dongjie ^{[1
]}

Li, Yanbo ^{[1
]}

Chen, Xiaohan ^{[5
]}

Lu, Yanping ^{[4
]}

Wang, Li ^{[1
]}

Lv, Wenliang ^{[1
]}

机构：

[1] Guanganmen Hosp, China Acad Chinese Med Sci, Dept Infect, Beijing 100053, Peoples R China

[2] Peking Univ, Peoples Hosp, Dept Tradit Chinese Med, Beijing 100044, Peoples R China

[3] Beijing Univ Chinese Med, Beijing 100105, Peoples R China

[4] Guangzhou Univ Chinese Med, Shenzhen Baoan Chinese Med Hosp, Dept Hepatol, Shenzhen 518100, Peoples R China

[5] Guanganmen Hosp, China Acad Chinese Med Sci, Dept Hematol, Beijing 100053, Peoples R China

来源：

INTERNATIONAL IMMUNOPHARMACOLOGY | 2024年 / 140卷

关键词：

Metabolic dysfunction-associated fatty liver; disease; MAFLD-HCC; Immunotherapy; Immune checkpoint inhibitors; Molecular targeted therapy; FATTY LIVER-DISEASE; NF-KAPPA-B; REGULATORY T-CELLS; NONALCOHOLIC STEATOHEPATITIS; INSULIN-RESISTANCE; SIGNALING PATHWAYS; HIPPO PATHWAY; NAFLD; NASH; HCC;

D O I：

10.1016/j.intimp.2024.112821

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Hepatocellular carcinoma (HCC) is a common cause of cancer-related mortality and morbidity globally, and with the prevalence of metabolic-related diseases, the incidence of metabolic dysfunction-associated fatty liver disease (MAFLD) related hepatocellular carcinoma (MAFLD-HCC) continues to rise with the limited efficacy of conventional treatments, which has created a major challenge for HCC surveillance. Immune checkpoint inhibitors (ICIs) and molecularly targeted drugs offer new hope for advanced MAFLD-HCC, but the evidence for the use of both types of therapy in this type of tumour is still insufficient. Theoretically, the combination of immunotherapy, which awakens the body's anti-tumour immunity, and targeted therapies, which directly block key molecular events driving malignant progression in HCC, is expected to produce synergistic effects. In this review, we will discuss the progress of immunotherapy and molecular targeted therapy in MAFLD-HCC and look forward to the opportunities and challenges of the combination therapy.

引用

页数：14

共 231 条

[1] RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma [J].

Akula, Shaw M. ;

Abrams, Stephen L. ;

Steelman, Linda S. ;

Emma, Maria R. ;

Augello, Giuseppa ;

Cusimano, Antonella ;

Azzolina, Antonina ;

Montalto, Giuseppe ;

Cervello, Melchiorre ;

McCubrey, James A. .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, :915-929

[2] The Role of Dendritic Cells in Fibrosis Progression in Nonalcoholic Fatty Liver Disease [J].

Almeda-Valdes, Paloma ;

Olivos, Nancy E. Aguilar ;

Barranco-Fragoso, Beatriz ;

Uribe, Misael ;

Mendez-Sanchez, Nahum .

BIOMED RESEARCH INTERNATIONAL, 2015, 2015

[3] Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma [J].

Anastasopoulos, Nikolaos-Andreas T. ;

Lianos, Georgios D. ;

Tatsi, Vera ;

Karampa, Anastasia ;

Goussia, Anna ;

Glantzounis, Georgios K. .

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 14 (11) :1025-1033

[4] Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study [J].

Anstee, Quentin M. ;

Lucas, Kathryn J. ;

Francque, Sven ;

Abdelmalek, Manal F. ;

Sanyal, Arun J. ;

Ratziu, Vlad ;

Gadano, Adrian C. ;

Rinella, Mary ;

Charlton, Michael ;

Loomba, Rohit ;

Mena, Edward ;

Schattenberg, Joern M. ;

Noureddin, Mazen ;

Lazas, Donald ;

Goh, George B. B. ;

Sarin, Shiv K. ;

Yilmaz, Yusuf ;

Martic, Miljen ;

Stringer, Rowan ;

Kochuparampil, Jossy ;

Chen, Li ;

Rodriguez-Araujo, Gerardo ;

Chng, Elaine ;

Naoumov, Nikolai V. ;

Brass, Clifford ;

Pedrosa, Marcos C. .

HEPATOLOGY, 2023, 78 (04) :1223-1239

[5] Research in Brief [J].

Baker, Holly .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (06) :508-508

[6] Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort [J].

Anstee, Quentin M. ;

Darlay, Rebecca ;

Cockell, Simon ;

Meroni, Marica ;

Govaere, Olivier ;

Tiniakos, Dina ;

Burt, Alastair D. ;

Bedossa, Pierre ;

Palmer, Jeremy ;

Liu, Yang-Lin ;

Aithal, Guruprasad P. ;

Allison, Michael ;

Yki-Jarvinen, Hannele ;

Vacca, Michele ;

Dufour, Jean-Francois ;

Invernizzi, Pietro ;

Prati, Daniele ;

Ekstedt, Mattias ;

Kechagias, Stergios ;

Francque, Sven ;

Petta, Salvatore ;

Bugianesi, Elisabetta ;

Clement, Karine ;

Ratziu, Vlad ;

Schattenberg, Joern M. ;

Valenti, Luca ;

Day, Christopher P. ;

Cordell, Heather J. ;

Daly, Ann K. .

JOURNAL OF HEPATOLOGY, 2020, 73 (03) :505-515

[7] From NASH to HCC: current concepts and future challenges [J].

Anstee, Quentin M. ;

Reeves, Helen L. ;

Kotsiliti, Elena ;

Govaere, Olivier ;

Heikenwalder, Mathias .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (07) :411-428

[8] Regulation of PD-L1 Expression by NF-κB in Cancer [J].

Antonangeli, Fabrizio ;

Natalini, Ambra ;

Garassino, Marina Chiara ;

Sica, Antonio ;

Santoni, Angela ;

Di Rosa, Francesca .

FRONTIERS IN IMMUNOLOGY, 2020, 11

[9] NF-KB dynamics in the language of immune cells [J].

Aqdas, Mohammad ;

Sung, Myong-Hee .

TRENDS IN IMMUNOLOGY, 2023, 44 (01) :32-43

[10] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study [J].

Armstrong, Matthew James ;

Gaunt, Piers ;

Aithal, Guruprasad P. ;

Barton, Darren ;

Hull, Diana ;

Parker, Richard ;

Hazlehurst, Jonathan M. ;

Guo, Kathy ;

Abouda, George ;

Aldersley, Mark A. ;

Stocken, Deborah ;

Gough, Stephen C. ;

Tomlinson, Jeremy W. ;

Brown, Rachel M. ;

Huebscher, Stefan G. ;

Newsome, Philip N. .

LANCET, 2016, 387 (10019) :679-690

← 1 2 3 4 5 6 7 8 9 10 →